To date, Hepabio has established collaborations with more than sixty leading pharmaceutical companies worldwide, including Roche, Hengrui, Hansoh, and BeiGene. These high-level partnerships demonstrate that Hepabio’s technology platform has become an integral component of the innovative drug development value chain, continuously supporting advances in global biomedicine.
Ms. Zhou Tingting - Founder and CEO
Ms. Zhou Tingting holds a Bachelor's degree from China Pharmaceutical University and a Master's degree in Medical Informatics from Karolinska Institutet in Sweden. With over a decade of deep experience in biopharmaceutical incubation and investment, she possesses extensive industry expertise and resource networks.
In 2022, Ms. Zhou Tingting founded Hepabio, focusing on the research and development of 3D microtissue platforms and organ-on-a-chip technologies. Under her leadership, the company has obtained a national invention patent, successfully completed an angel round of financing, and established stable collaborations with over sixty leading domestic pharmaceutical companies, including Roche, BeiGene, Hengrui, and Hansoh. Additionally, in 2025, she participated in drafting the group standard "Technical Specification for Drug Toxicity Evaluation Based on Organoid Models (T/C1ET1854-2025)" and received an honorary certificate from the Standardization Work Committee of the China International Economic and Technical Cooperation Promotion Association. Ms. Zhou Tingting also serves as a committee member of the Organoid and Organ-on-a-Chip Expert Committee of the Chinese Society of Toxicology and as the Deputy Secretary-General of the Shanghai Alumni Association of China Pharmaceutical University. She is committed to advancing the integration of industry, academia, and research, facilitating the translation of international scientific and technological achievements, and building a critical bridge connecting global biopharmaceutical innovation resources.
Prof. Volker M. Lauschke, PhD, MBA - Co-founder and CSO
Volker is Professor in Translational Pharmacology at Karolinska Institutet, Stockholm and Deputy Head of the Bosch Institute of Clinical Pharmacology in Stuttgart, Germany. In his research, he develops 3D cell culture systems of primary human cells and uses these organotypic systems for phenotypic and chemogenomic screening to discover novel therapeutic strategies for MASH/fibrosis, infectious diseases and complex metabolic disorders. In addition, his group develops machine learning tools to improve personalized pharmacological therapy and establish novel methods for the prediction of drug toxicity. V.M.L. has authored over 180 papers, is a Clarivate Highly Cited Researcher and is the recipient of multiple awards in the area of genetics, pharmacology and drug discovery, including the Malin and Lennart Philipson Prize, the AAPS High Impact Award and the ISSX Karl Netter Award.
Contact Way